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INTRODUCTION
Unverricht-Lundborg disease (ULD) (EPM1, OMIM 254800) 
is the “purest” type and the most common form of progressive 
myoclonic epilepsy (PME).1,2 It is characterized by symptoms 
of myoclonic jerks and generalized tonic-clonic seizures 
(GTCSs), which are caused by photic or touching stimulus 
and usually occur at the age 6−16 years.3 This disease is an au-
tosomal recessive disorder, and the CSTB gene encoding cys-
tatin B, a cysteine protease inhibitor, is the only gene known 
to be associated with ULD.4 The 12-nucleotide dodecamer re-
peat (5’-CCC-CGC-CCC-GCG-3’) expansion in the promotor 
region of CSTB accounts for approximately 90% of cases 
worldwide and 99% of the EPM1 cases in Finland.5 Loss of ly-
sosomal linkage and an endogenous neuroprotective role of 
CSTB are known as the main pathological mechanisms of the 
disease.6 Here, we report a patient with ULD and her families 
diagnosed by Southern blot analysis. It is the first case of a ge-
netically confirmed ULD in Korea. This study was approved 
by the Institutional Review Board of Severance Hospital.
CASE REPORT
A 20-year-old woman presented with both uncontrolled hand 
tremor and seizure attacks. The perinatal and infancy periods 
of the patient were not eventful, and early developmental mile-
stones were normal. She developed myoclonic movements of 
the whole body at the age of 10 years. The myoclonic move-
ments became aggravated gradually with more severe in-
volvement of both upper limbs. They occurred frequently ev-
ery day, more severe on settling into sleep and awakening, 
and their severity was reduced after turning off the light. They 
were provoked upon sudden movements, such as standing 
up. Also, tremulous movements of both hands (small ampli-
tude jerks) occurred persistently. They increased in severity as 
the hand moved closer to its target; therefore, detailed hand 
movements, such as when operating a cell phone, were diffi-
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cult. Also, she could not run because of provoked myoclonic 
movements since the age of 13 years. Dysarthric speech and 
gait disturbance were recognized around that time and be-
came gradually aggravated. She had developed mild intellec-
tual disability since the age of 10 years. The results of neuropsy-
chological tests (Korean-Wechsler Intelligence Scale for 
Children-III) taken at the age of 15 years showed mild mental 
retardation [full-scale intelligence quotient (IQ)=65, verbal 
IQ=61, and performance IQ=75]. Also, she showed emotional 
liability. GTCSs following a series of myoclonic movements 
occurred for the first time, a half year after the occurrence of 
myoclonus. GTCSs were mainly provoked by bright lights or 
emotional stress and occurred once a week. At that time, she 
began to receive treatment with antiepileptic drugs (AEDs). 
Her seizures, including myoclonic movements and GTCSs, 
were aggravated with oxcarbazepine, carbamazepine, and la-
motrigine treatment, and significantly improved, particularly 
in GTCS, with valproic acid treatment. Frequency of GTCS was 
reduced to three or four times a year.
At the age of 20 years, she was admitted to our hospital due 
to aggravation of GTCS control (two times per month). She 
had been treated with levetiracetam (2000 mg/day), valproic 
acid (500 mg/day), clonazepam (0.75 mg/day), baclofen (20 
mg/day), and lorazepam (1.5 mg/day). On neurologic exami-
nation, the almost continuous, tremulous movements of both 
hands were observed. Relatively large amplitude myoclonic 
movements occurred intermittently, particularly when moving 
suddenly, and were also provoked with arm stretching and 
hand extension. Also, she showed a mild degree of dysarthria, 
dysmetric limb ataxia, and truncal ataxia on tandem gait. The 
patient’s 15-year-old sister had normal cognition and no neu-
rologic symptoms. Her father had experienced several sei-
zures after head trauma in his 30s. After taking AEDs for three 
years, seizures no longer developed. Also, this family had no 
ancestors from other countries. Other family history was un-
remarkable (Fig. 1).
Continuous video-electroencephalography (EEG) was per-
formed. The EEG showed intermittent generalized sharp 
waves with posterior emphasis, although the myoclonic move-
ments, including the almost continuous, small amplitude jerks, 
were not time-locked to EEG discharges. Background rhythm 
on EEG was normal with well-regulated 10-Hz posterior domi-
nant rhythm. Photic stimuli could not provoke electrical and 
clinical seizure. Brain magnetic resonance imaging and mag-
netic resonance spectroscopy revealed no abnormalities. So-
matosensory-evoked potential and visual-evoked potential 
tests showed normal latencies, shapes, and amplitudes. 
CSTB gene-associated dodecamer repeat expansion was 
analyzed by Southern blot analysis after obtaining informed 
consent. Genomic DNA was extracted from peripheral blood 
leukocytes using the Wizard Genomic DNA Purification kit 
(Promega, Madison, WI, USA) according to the manufacturer’s 
instructions. Southern blot analysis was performed at Athena 
Fig. 1. The pedigree of our patient (arrow). Her father was treated with 
symptomatic seizures after sustaining head trauma in a car accident on 
his 30s. Other family history was unremarkable.
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Fig. 2. Southern blot analysis showing enlarged restriction fragments in 
our patient. Positive control shows enlarged fragments with expanded 
size of 39 dodecamer repeats and 81 dodecamer repeats, respectively, 
and the negative control shows normal fragments with six repeats. Our 
patient exhibited a homozygous expanded CSTB fragment with 62 re-
peats, and her parent and sister were carriers with a heterozygous ex-
panded CSTB fragment.
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Diagnostics Inc. (Marlborough, MA, USA). The patient showed 
only abnormally enlarged restriction fragments of 62 dodecam-
er repeats, confirming ULD, that were transmitted from her 
father and mother who carried the abnormally enlarged re-
striction fragments as heterozygotes with normal-sized frag-
ments (Fig. 2). Her sister, also a heterozygote, carried the ex-
panded fragment as a carrier.
We changed AEDs for seizure control. Upon discontinuing 
clonazepam, baclofen, and lorazepam, the patient was treated 
with valproic acid (1250 mg/day), levetiracetam (2000 mg/day), 
clobazam (10 mg/day), and zonisamide (300 mg/day). GTCS 
did not recur in the following 9 months. Further, her small 
amplitude jerks of both hands much decreased. 
DISCUSSION
The present patient’s clinical manifestations were compatible 
with PMEs related to several etiologies. ULD has rather milder 
symptoms than other PMEs. Our patient experienced gradu-
ally worsening, but mild neurological symptoms and preser-
vation of normal EEG background activity. Therefore, these 
clinical features and the disease course of our patient were re-
garded as the typical clinical manifestations of ULD. If there is 
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a severe progression in cognitive or visual symptoms, other 
forms of PME, such as myoclonic epilepsy with ragged red fi-
bers, neuronal ceroid lipofuscinosis, Lafora’s disease, and si-
alidosis, should be suspected.7 Recent study suggests that lon-
ger CSTB expansion mutations have a modulating effect on 
age at disease onset, myoclonus severity, and cortical neuro-
physiology in ULD.5 Abnormal CSTB gene-associated do-
decamer repeat expansion was confirmed by Southern blot, 
leading to the diagnosis of ULD. Normal alleles of the CSTB 
gene contain two to three dodecamer repeats and full-pene-
trance alleles of more than 30 repeats.8 The size of fully ex-
panded alleles and GC-rich sequences in the dodecamer re-
peat region make conventional PCR extremely difficult and 
require laborious Southern blot analysis. More convenient di-
agnostic testing (the dodecamer repeat analysis method, such 
as repeat PCR assay) needs to be developed in the future.
Although the prevalence of ULD is high in the Mediterra-
nean and Finland, sporadic cases have been diagnosed world-
wide, including Japan.5,9 However, the recognition of ULD is 
still lacking in areas of low prevalence due to varying availabil-
ity of molecular diagnostic techniques and since it is difficult 
to diagnose ULD with clinical symptoms alone.10 To our knowl-
edge, our patient is the first case to be confirmed genetically 
in Korea. In patients with intractable myoclonus or myoclonic 
epilepsy, especially with onset after the age of 6 years, analysis 
of the CSTB gene using Southern blot analysis will help to de-
fine the syndrome. Also, adequate choices of AEDs might be 
important in treatment of symptoms in ULD. Carbamazepine, 
oxcarbazepine, and lamotrigine may paradoxically worsen 
myoclonus as seen in our patient. An inverse pharmacodynam-
ics effect is suggested as the main mechanism of aggravation 
of myoclonic seizures.11
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